FREZENT Biological Solutions
Eliminating the threat of recurrent cancer.
New York · Founded 2017 · $100K raised
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2017
- Website
- frezent.com
- Total Funding
- $100K
- Last Round
- $100K Pre-Seed
- Rounds
- 1
About
FREZENT Biological Solutions is a New York-based preclinical oncology therapeutics company founded by Dr. Natasha Shtraizent and Dr. Lina Freage-Kahn. Its mission is to eliminate the threat of recurrent cancer by developing novel bispecific antibodies and biological inhibitors targeting cancer-specific lipid metabolism pathways. The company focuses on extending lives of advanced-stage cancer patients by targeting dormant cancer cells that drive recurrence. FREZENT was selected for the 2025 MSK Therapeutics Accelerator cohort at Memorial Sloan Kettering Cancer Center.
Summary
FREZENT Biological Solutions is a company based in New York, founded in 2017. It has raised $100K in total across 1 round. Investors include SOSV, IndieBio and New York Ventures.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Unknown
